The incidence of
non-small-cell lung cancer (NSCLC) in Russia is the highest among the BRIC
(Brazil, Russia, India, China) markets, and is comparable to that of the United
Kingdom and the United States. Increasing risk of non-small-cell lung cancer
due to increasing smoking prevalence, in conjunction with an aging population,
will drive an increase in incident non-small-cell lung cancer cases in Russia
through 2020. In this report, we examine the trends within Russia’s NSCLC
therapy market, which is characterized by the growing incident
population, gradually increasing use of higher-priced
chemotherapies and the introduction of several premium-priced
Questions Answered in This Report:
Incidence of NSCLC in Russia is the highest in BRIC markets
and is comparable to that of the United Kingdom and the United States. How does
incidence of NSCLC translate into drug-treated NSCLC cases in Russia? Will
population dynamics and rates of treatment across all stages of NSCLC sustain
commercial opportunity in Russia through 2015?
Reimbursement policies in both the public and private sectors are a major
factor influencing expenditure on NSCLC treatments in Russia. Which groups
of Russian patients are eligible for government-reimbursed treatment of NSCLC?
What types of treatment are included in the Additional Drug Coverage? Which
therapies are not readily reimbursed to the Russian patients by the government
and what are the current patient shares of those therapies?
In 2010, the most commonly prescribed agents for the treatment of NSCLC were
different in Russia to those most commonly prescribed in the major markets for
the same indication. What are the most-prescribed regimens for the treatment
of NSCLC in Russia, across all stages? How much influence does histology type
have on Russian physicians’ prescription choices? How do molecular testing
practices vary between Russia and the major markets, in the context of NSCLC?
Primary research: 90 oncologists surveyed across Russia
(including 60 oncologists surveyed in four major cities [Moscow, Saint
Petersburg, Novosibirsk, and Ekaterinburg]). Separate in-depth interviews with 8
Epidemiology: Total incident cases of NSCLC in Russia
over a ten-year period (2010-2020) by age, by gender, by histology, by Federal
District, and by major city.
Current therapies and medical practice: Reporting use
of brands and generics for the NSCLC treatments available in Russia.
Pricing and reimbursement: Prices of NSCLC therapies
in Russia versus other major markets and analysis of the impact of government
reimbursement on treatment trends.
Market forecast features: Our analysis evaluates
rates of NSCLC progression and rates of drug treatment with NSCLC therapies,
across all stages of the disease. We include a detailed forecast of current and
emerging therapies within platinum agents, taxanes, antimetabolites, vinca
alkaloids, topoisomerase II inhibitors, DNA-interacting agents, VEGF/EGFR
monoclonal antibodies, kinase inhibitors, and PARP inhibitors classes of drugs,
from 2010 through 2015, using a combination of historical trend analysis and an
epidemiology-based, bottom-up market model.